Sichuan Baili Pharmaceutical Co., Ltd.
Hefei, Anhui
What changed
Phase I trial registered: Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
9mo agoTrial registeredSep 26, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 45 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase I
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
P41 · $230k · non-dilutive
Jun 20, 2022UNIVERSITY OF CALIFORNIA AT DAVIS · PI QI, JINYI · NIBIB · award ends Mar 31, 2027 · TRD3: Data Analytics and Intelligent Systems (AI-ML-DL-Visualization)
NIH RePORTER · NIH RePORTER 11105989 (opens the source filing in a new tab)
- Trial
PHASE1 registered
Nov 4, 2020Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia · ACTIVE_NOT_RECRUITING · sponsor: Sichuan Baili Pharmaceutical Co., Ltd. · Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
ClinicalTrials.gov · NCT04606433 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources